Goldman Sachs starts MeiraGTx coverage with a USD 16 target for MeiraGTx stock
Goldman Sachs has initiated coverage of MeiraGTx (MGTX) with a Neutral rating and a USD 16.00 price target, citing regulatory uncertainty surrounding the company's lead gene therapy program. The target represents a 50.09 percent increase from its last Nasdaq price. MeiraGTx reported a significant jump in second-quarter revenue to USD 321.43 million, driven largely by licensing and collaboration income, despite negative operating cash flow.
Meiragtx Holdings Plc (MGTX-Q) Stock Price and News
This article provides comprehensive information on Meiragtx Holdings Plc (MGTX-Q), including its stock price, recent news, financial data, and analyst ratings. It highlights various news items such as board appointments, strategic investments, and financial results, along with stock performance metrics. The company profile identifies MeiraGTx as a clinical-stage gene therapy company developing treatments for inherited and acquired disorders.
Form 4 MeiraGTx Holdings PLC For: 28 September By Investing.com
This article announces the filing of Form 4 by MeiraGTx Holdings PLC for September 28. It includes general market data and related news but does not provide specific details about the Form 4 filing itself. The article was published by Investing.com.
Form 4 MeiraGTx Holdings PLC For: 28 September By Investing.com
This article reports on a Form 4 filing for MeiraGTx Holdings PLC on September 28, 2026. Form 4s are SEC filings used to disclose changes in beneficial ownership of securities by company insiders. The content is brief and serves as an announcement for this regulatory filing.
MGTX Initiated Coverage by Goldman Sachs -- Price Target Announced at $16
Goldman Sachs initiated coverage on MeiraGTx Holdings (MGTX) with a Neutral rating and a $16.00 price target. Despite this cautious outlook, GuruFocus indicates MGTX is significantly undervalued, trading at an 86.0% discount to its GF Value™ of $80.20, although insider selling and a moderate GF Score™ of 63/100 suggest caution for investors.
MeiraGTx (MGTX) director Alan Sebulsky reports shares held through an LLC he manages.
MeiraGTx director Alan Sebulsky reported an indirect holding of 34,500 ordinary shares through Apothecary Capital LLC as of September 23, 2026. Sebulsky, as the LLC's managing member, shares voting, investment, and dispositive power but disclaims beneficial ownership for Section 16 purposes, except for any pecuniary interest. This disclosure outlines his indirect ownership structure and clarifies his beneficial interest in the shares.
A 100,000-unit share award for MeiraGTx (MGTX) director Alan Sebulsky vests over three years.
MeiraGTx Holdings plc director Alan Sebulsky was granted 100,000 restricted share units (RSUs) on September 23, 2026. These RSUs will convert into ordinary shares upon vesting, with one-third of the award vesting on each of the first, second, and third anniversaries of the grant date. This transaction was reported via a Form 4 filing and indicates a neutral impact and sentiment according to Rhea-AI.
Form 4 MeiraGTx Holdings PLC For: 24 September By Investing.com
The article reports that MeiraGTx Holdings PLC filed a Form 4 for September 24. This filing is a standard SEC document used to report changes in beneficial ownership of a company's securities by officers, directors, or significant shareholders. The article itself is brief, primarily serving as an announcement of the filing rather than providing detailed analysis.
Goldman Sachs Initiates MeiraGTx at Neutral With $16 Price Target
Goldman Sachs has initiated coverage on MeiraGTx Holdings (MGTX) with a Neutral rating and set a price target of $16. This report comes as MeiraGTx, a clinical-stage genetic medicines company, continues to advance its late-stage clinical programs. The company's stock was recently trading at $11.13.
MeiraGTx Appoints Healthcare Investor Alan Sebulsky to Board of Directors
MeiraGTx Holdings plc has appointed Alan M. Sebulsky, a veteran healthcare investor with over 40 years of experience, to its Board of Directors. Sebulsky, who most recently served as a partner and portfolio manager at Adage Capital Management and founded Apothecary Capital, brings valuable capital markets and biopharmaceutical investment experience. This appointment is strategic as MeiraGTx advances its late-stage clinical programs and aims to transition into a commercial-stage genetic medicines company.
MeiraGTx appoints Alan M. Sebulsky to its Board as Class I director
MeiraGTx has appointed Alan M. Sebulsky as a Class I director to its Board, effective September 23, 2026. He will also serve on the Science and Technology Committee. Sebulsky brings extensive financial experience, having previously served as a Managing Member of Apothecary Capital LLC and a Partner & Portfolio Manager at Adage Capital.
An investor who led a team overseeing over $2 billion in drug-company assets joins MeiraGTx's board.
MeiraGTx Holdings plc (MGTX) has appointed Alan M. Sebulsky, a veteran healthcare portfolio manager, to its Board of Directors. Sebulsky brings over 40 years of experience in public company investment and financial strategy, including leading a diversified biopharmaceutical portfolio with over $2 billion in assets at Adage Capital Management. His expertise is expected to be valuable as MeiraGTx advances its genetic medicine programs and aims to transition into a commercial company.
MeiraGTx Holdings plc Announces Appointment of Alan M. Sebulsky to its Board of Directors
MeiraGTx Holdings plc has appointed Alan M. Sebulsky as a Class I director to its Board of Directors, effective September 23, 2026. Mr. Sebulsky will also serve as a member of the Science and Technology Committee. He brings over 40 years of experience as a healthcare portfolio manager and biopharmaceutical investment analyst, having previously served as Partner and Portfolio Manager at Adage Capital Management and as the founder of Apothecary Capital.
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
Shares of MeiraGTx Holdings PLC (MGTX) have gained 28.1% recently, and Wall Street analysts project a potential upside of 128.1%, with a mean estimate of $28.38. While price targets are often debated for their accuracy and potential bias, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) for MGTX suggest a legitimate reason to anticipate an upside in the stock. Investors are advised to use price targets with skepticism but consider the agreement among analysts and positive earnings outlook as a starting point for further research.
Why MeiraGTx (MGTX) Is Up 7.7% After Swing to Q2 Profitability and New Leadership Hires
MeiraGTx Holdings plc saw its shares rise 7.7% after reporting a significant swing to profitability in Q2 2026, with revenue reaching US$321.43 million and net income US$160.72 million. The company also announced the appointment of Penny Fleck and John Knighton to senior development and manufacturing roles, reinforcing its operational depth. This turnaround and new leadership are reshaping the investment narrative for MeiraGTx, emphasizing its potential for durable, product-based cash flows beyond one-off deals.
Tocqueville Asset Management L.P. Makes New $1.05 Million Investment in MeiraGTx Holdings PLC $MGTX
Tocqueville Asset Management L.P. has made a new $1.05 million investment in MeiraGTx Holdings PLC (NASDAQ:MGTX), purchasing 77,700 shares. This increases institutional ownership to 67.48% of the company, with other firms like BlackRock Inc. and Deutsche Bank AG also acquiring new positions. The company recently reported strong quarterly results, beating EPS and revenue estimates, but has also seen insider selling activity.
Meiragtx CEO Forbes sells $859,320 in company stock
MeiraGTx Holdings plc CEO Alexandria Forbes sold 62,000 ordinary shares worth $859,320 on August 18, 2026, as part of a pre-arranged trading plan. Despite the sale, Forbes still directly owns over 1.3 million shares. The company's stock is trading near its 52-week high, and InvestingPro analysis suggests it is fairly valued with "GREAT" financial health.
MeiraGTx CEO Alexandria Forbes sells 62,000 shares for $859,320
MeiraGTx President and CEO Alexandria Forbes sold 62,000 ordinary shares on August 18, 2026, for $13.86 per share, totaling $859,320. This transaction reduced her direct holding to 1,325,695 ordinary shares. The information was originally published via EDGAR by MeiraGTx Holdings plc.
Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com
Alexandria Forbes, CEO of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 62,000 ordinary shares for $859,320 on August 18, 2026, as part of a Rule 10b5-1 trading plan. The shares were sold at an average price of $13.86, with Forbes directly owning 1,325,695 shares afterward. This transaction follows other company news, including a significant $400 million financial agreement with Oberland Capital and a reiterated Buy rating from H.C. Wainwright.
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
MeiraGTx CEO Alexandria Forbes sold 62,000 shares of the company's stock for approximately $859,320 at an average price of $13.86, reducing her stake by 4.47%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. MeiraGTx shares traded up 0.9% to $13.89, with the company recently reporting strong quarterly earnings of $1.71 per share against analyst expectations of ($0.46) and revenue of $321.43 million.
Meiragtx CEO Forbes sells $859,320 in company stock
MeiraGTx Holdings plc CEO Alexandria Forbes sold 62,000 ordinary shares for $859,320 as part of a pre-planned trading strategy. Following the sale, Forbes still directly owns over 1.3 million shares. The company recently secured up to $400 million in financing and received a reiterated Buy rating from H.C. Wainwright.
MeiraGTx (MGTX) holder readies new sale after recent 62K-share cashout
MeiraGTx Holdings plc (MGTX) has filed a Rule 144 notice indicating that Alexandria Forbes plans to sell 62,000 ordinary shares through Merrill Lynch, with an aggregate market value of $859,320. These shares were originally acquired on June 7, 2018, as an Incentive Compensation Stock Grant. The filing also reports that Forbes previously sold 62,000 ordinary shares on May 19, 2026, for $568,540.
MeiraGTx (MGTX) CEO sells 62K shares in preset plan at $13.86
MeiraGTx Holdings plc (MGTX) CEO Alexandria Forbes sold 62,000 Ordinary Shares at a weighted average price of $13.86 per share on August 18, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the sale, Forbes directly holds 1,325,695 Ordinary Shares of MeiraGTx.
Johnson & Johnson Takes $89.72 Billion Position in MeiraGTx Holdings PLC $MGTX
Johnson & Johnson has acquired 6.64 million shares of MeiraGTx Holdings PLC, valued at approximately $89.72 billion, making it J&J's third-largest portfolio holding. This significant investment comes as MeiraGTx reported strong second-quarter earnings, exceeding analyst expectations, and received FDA Breakthrough Therapy Designation for one of its gene therapies. Despite the positive outlook from analysts, concerns about shareholder dilution from recent equity financing exist.
Profit Surge and New Leadership Might Change The Case For Investing In MeiraGTx Holdings (MGTX)
MeiraGTx Holdings (MGTX) recently reported a significant turnaround in its Q2 2026 financial results, with revenue jumping to US$321.43 million and net income improving to US$160.72 million from a previous loss. This shift to profitability, coupled with new leadership hires experienced in gene therapy commercialization, aims to re-position MeiraGTx as a fully integrated gene therapy company. Investors, however, should consider the sustainability of these profits and potential future dilution despite the positive near-term narrative.
Rubric Capital discloses 9.83% MeiraGTx (MGTX) position totaling 9.1M shares
Rubric Capital Management LP and David Rosen have reported a beneficial ownership of 9.83% in MeiraGTx Holdings plc, amounting to 9,100,000 Ordinary Shares. This disclosure was made in an amended Schedule 13G filing, indicating shared voting and dispositive power over these shares, which are held through Rubric-managed funds. The ownership percentage is based on 92,609,516 Ordinary Shares outstanding as of May 8, 2026.
MeiraGTx (MGTX) Stock Jumps After Profit Shock Raises Durability Questions
MeiraGTx (MGTX) stock surged 6.7% after the company reported a significant and unexpected swing to profitability in Q2 2026, with basic EPS of US$1.76 and net income of US$160.72 million on US$321.43 million in revenue. This profit surprise, combined with late-stage pipeline progress and non-dilutive funding, suggests an evolution from a pure pipeline story to a more financially grounded platform. However, the durability of these earnings is questioned, as clinical-stage biotech profits can be volatile and potentially stem from one-off events, leaving the stock's long-term risk profile still in view.
MeiraGTx Holdings Releases Q2 2026 Financial Results
MeiraGTx Holdings plc reported a significant turnaround in Q2 2026, swinging to profitability with diluted earnings per share of $1.71, compared to a loss in the previous year. The company achieved substantial revenue growth, reaching $321.4M from $3.7M in Q2 2025, indicating a commercial milestone in its genetic medicines pipeline. Wall Street analysts maintain a bullish outlook on the stock, reflecting strong investor confidence in MeiraGTx's commercialization efforts and genetic medicines portfolio.
Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX
Sei Investments Co. has acquired 99,627 shares of MeiraGTx Holdings PLC (MGTX) worth approximately $863,000, as part of broader institutional investor interest in the company. Despite significant insider selling totaling $1.68 million over the last three months, MeiraGTx reported strong quarterly EPS of $1.71, surpassing estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $26. The company is a clinical-stage biotechnology firm focused on developing gene therapies for rare diseases.
Why is MeiraGTx stock surging today?
MeiraGTx Holdings PLC stock surged 6.3% following a dramatic beat on Q2 2026 earnings, reporting $1.71 EPS against an expected loss and revenue of $321.4 million. The company's financial turnaround was supported by strategic deals, FDA Breakthrough Therapy Designation, and a significantly strengthened balance sheet. These positive developments, combined with a favorable market, suggest an accelerating transformation for MeiraGTx from a clinical-stage developer to a revenue-generating enterprise.
MeiraGTx Holdings Releases Q2 2026 Financial Results
MeiraGTx Holdings plc (MGTX) reported a significant turnaround in Q2 2026, swinging to profitability with diluted earnings per share of $1.71 and net income of $160.7M. The company's revenue surged to $321.4M from $3.7M in Q2 2025, indicating a major commercial milestone in its transition from a clinical-stage to a commercial-stage genetic medicines firm. Wall Street analysts maintain a bullish stance on the stock, reflecting investor confidence in MeiraGTx's genetic medicines portfolio.
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) reported Q2 earnings of $1.71 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.39 per share, and revenue of $321.43 million, which also surpassed expectations. Despite the strong quarterly performance, the company holds a Zacks Rank #3 (Hold), suggesting its shares are expected to perform in line with the market in the near future. MeiraGTx shares have seen a 63% increase year-to-date, outperforming the S&P 500.
Form 8K MeiraGTx Holdings PLC For: 13 August By Investing.com
This article reports on a Form 8K filing by MeiraGTx Holdings PLC for August 13th, as published by Investing.com. It is a brief announcement without further details regarding the content of the filing. The article is primarily a placeholder for the SEC filing information.
MeiraGTx Holdings plc 2026: Revenue $321.43M, EPS $1.71— 10-Q Summary
MeiraGTx Holdings plc reported strong financial results for the 2026 quarter, with revenue soaring to $321.43 million and diluted EPS reaching $1.71. This significant growth was primarily driven by increased service and related-party revenue from a Lilly contract, as well as the recognition of deferred arrangements. The company also highlighted pipeline advancements, strategic collaborations, and manufacturing progress in its business highlights.
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
MeiraGTx Holdings plc announced its second-quarter 2026 financial and operational results, highlighting significant progress in transforming into a commercial company. Key achievements include the acquisition of botaretigene sparoparvovec (bota-vec) for XLRP, FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia (RIX) with positive three-year data, and securing up to $400 million in strategic investment from Oberland Capital. The company plans global regulatory filings for bota-vec in 2026 and a potential BLA filing for AAV2-hAQP1 in mid-2027, alongside advancing its Riboswitch platform and other programs.
MeiraGTx Reports $321.4 Million Revenue and $160.7 Million Quarterly Net Income
MeiraGTx Holdings plc (MGTX) announced strong second-quarter 2026 results, reporting $321.4 million in total revenue and $160.7 million in net income. The company achieved significant milestones, including FDA Breakthrough Therapy Designation for AAV2-hAQP1, the acquisition of bota-vec rights from Johnson & Johnson, and a substantial investment agreement with Oberland Capital. Insider trading activity showed sales by key executives, while hedge funds exhibited mixed but largely positive sentiment, with several firms significantly increasing their stakes.
MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Rating of "Moderate Buy" by Brokerages
MeiraGTx Holdings PLC (NASDAQ:MGTX) has received an average "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $26.00, significantly above its current trading price of $12.96. Despite recent insider share sales by the CEO and CFO totaling $1.68 million, insiders still retain a 7.4% ownership stake. The company, which has a market capitalization of $1.2 billion, reported a quarterly loss of $0.57 per share but revenue of $0.29 million, falling short of analyst expectations.
MeiraGTx Holdings PLC (MGTX) Stock News Today
This article from TradingKey provides stock information for MeiraGTx Holdings PLC (MGTX). It includes current stock price, market capitalization, and indicates that more news, earnings, and analyst ratings for MGTX are expected soon. The page serves as a hub for MGTX stock-related updates.
MeiraGTx Holdings plc (MGTX) Stock Analysis: Exploring a 128.97% Potential Upside in the Biotech Arena
MeiraGTx Holdings plc (NASDAQ: MGTX) is a clinical-stage biotechnology company with a market capitalization of $1.18 billion, focusing on genetic therapies for ocular, neurodegenerative, and autoimmune diseases. Analysts show strong optimism with all seven ratings being "Buy" and an average target price of $29.29, suggesting a 128.97% potential upside despite recent revenue decline. The company is strategically positioned with a robust pipeline, strong cash flow, and collaborations with industry leaders, making it an intriguing, albeit risky, investment in the biotech sector.
MeiraGTx grants new hire 75,000 stock options under inducement plan
MeiraGTx has granted a new hire 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) under its 2026 Employment Inducement Award Plan. The stock options will vest over 36 months, with 25% after one year, while the RSUs will vest 50% after two years and then 25% in years three and four, all contingent on continued employment.
MeiraGTx Holdings PLC (MGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
MeiraGTx Holdings PLC (MGTX) has an earnings forecast score of 8.50, ranking 108th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $27.00 for MGTX, with a "Buy" trend based on ratings from 7 analysts. The company's expected revenue for the next quarter is $12.48 million, and EPS for the next quarter is anticipated to be -$0.46.
MeiraGTx grants new hire 75,000 stock options under inducement plan
MeiraGTx has granted a new hire 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) under its 2026 Employment Inducement Award Plan. The stock options are priced at the Nasdaq closing price on the employee's start date and vest over four years, while the RSUs also vest over four years with specific percentages at two, three, and four years. This move is designed to incentivize and retain the new employee.
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MeiraGTx Holdings plc announced that its Compensation Committee approved equity awards for a new employee. These awards, consisting of non-qualified stock options and time-based restricted stock units, were granted as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are subject to vesting schedules tied to continued employment.
A new MeiraGTx employee receives 150,000 equity awards
MeiraGTx (Nasdaq: MGTX) announced that its Compensation Committee approved an inducement grant of 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) for a new employee. These awards, made under Nasdaq Listing Rule 5635(c)(4), are contingent on continued employment, with specific vesting schedules over one to four years. The stock options' exercise price will be the closing price of MeiraGTx ordinary shares on the employee's start date.
MeiraGTx Holdings PLC (328.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance
The article provides an overview of analyst recommendations and price targets for MeiraGTx Holdings PLC (328.SG). It lists several recent analyst actions, including RBC Capital and HC Wainwright & Co. maintaining "Outperform" and "Buy" ratings respectively. The stock currently trades at 11.10 EUR with no change, as of the latest market data.
MeiraGTx Holdings (Nasdaq:MGTX) - Stock Analysis
MeiraGTx Holdings (MGTX) is a clinical-stage genetic medicines company with a market cap of US$1.1 billion. The company faces financial risks including negative shareholder equity, unprofitability, and past shareholder dilution, though revenue is forecast to grow significantly. Recent developments include a $400 million financing package to accelerate its gene therapy pipeline, positive clinical trial data for AAV-hAQP1 in radiation-induced xerostomia, and FDA Regenerative Medicine Advanced Therapy (RMAT) designations for AAV-GAD and AAV2-hAQP1.
MeiraGTx Holdings PLC (MGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of MeiraGTx Holdings PLC (MGTX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. While the current price momentum score is 4.55 within the Biotechnology & Medical Research industry, technical indicators collectively suggest a "Neutral" signal for the stock. The article advises that MGTX is currently trading between specified resistance and support levels, making it potentially suitable for range-bound swing trading.
MGTX|MeiraGTx Holdings PLC|Price:11.810|Chg%:-0.490
MeiraGTx Holdings PLC (MGTX) has a high growth potential and relatively healthy fundamentals, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. The company, a clinical-stage genetic medicines firm with several late-stage clinical programs, has shown strong revenue and profit growth. Analysts have rated it as a Buy, with expectations for its stock price to trend upward in the medium term despite recent weak market performance.
Price to earnings forward of MeiraGTx Holdings Plc – LS:A2JGHF
This article provides financial information for MeiraGTx Holdings Plc, identified by the stock symbol LS:A2JGHF on the Lang & Schwarz Tradecenter. It specifically focuses on the company's forward price-to-earnings ratio and indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial platform, offering an overview of the company's financials, news, and technical data.
Rubric Capital Management LP Acquires 824,669 Shares of MeiraGTx Holdings PLC $MGTX
Rubric Capital Management LP increased its stake in MeiraGTx Holdings PLC by 13.4% in the first quarter, purchasing 824,669 additional shares and bringing its total holdings to 7 million shares, representing 7.56% of the company. Despite reporting a quarterly loss of $0.57 per share (better than estimates) and revenue of $0.29 million (below consensus), MeiraGTx maintains an average "Moderate Buy" rating from analysts with a $26 price target. Institutional investors collectively own 67.48% of the stock, while company insiders hold 7.40% and have recently sold shares under Rule 10b5-1 trading plans.
